Health
Novel prostate cancer resistance mechanism could be a promising target – Drug Target Review
By inhibiting the activity of microRNA-194 (miR-194), scientists prevented prostate cancer cells from developing treatment resistance.
Posted: 6 January 2021 | Hannah Balfour (Drug Target Review) | No comments yet
By inhibiting the activity of microRNA-194 (miR-194), scientists prevented prostate cancer cells from developing treatment resistance in vitro.
Researchers have identified a new mechanism through which prostate cancer cells convert to a more aggressive subtype in response to hormonal therapies. According to the team, further exploration of their findings may enable scientists to develop more targeted ways to remedy treatment…
-
General21 hours agoCoalition abandons ‘end’ to work from home, walks back 41,000 job cuts
-
Noosa News11 hours agoBanana farmers still salvaging fruit four weeks after ex-Tropical Cyclone Alfred
-
Business15 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
Business11 hours ago1 ASX dividend stock down 43% I’d buy right now